2007
|
Sign up to set email alerts
|

Abstract: Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprola… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
16
0

Year Published

2009
2009
2013
2013

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 21 publications
(17 citation statements)
references
References 14 publications
(19 reference statements)
1
16
0
Order By: Relevance
“…Nevertheless, this drug should be considered because of its promising perspective based on actual clinical experiences. Even in “refractory” TS, aripiprazole has shown about 75% reduction of severe coprolalia in a 28-year-old man [16] as well as good efficacy in treating TS and coexisting OCD in an adult female [283]. Accordingly, Budman et al [32] found in their retrospective, observational study of 37 children and adolescents with TS who were refractory to previous treatment that aripiprazole still reduced tics as well as explosive outbursts in these patients.…”
Section: Pharmacological Treatment Options For Tsmentioning
confidence: 99%
“…Nevertheless, this drug should be considered because of its promising perspective based on actual clinical experiences. Even in “refractory” TS, aripiprazole has shown about 75% reduction of severe coprolalia in a 28-year-old man [16] as well as good efficacy in treating TS and coexisting OCD in an adult female [283]. Accordingly, Budman et al [32] found in their retrospective, observational study of 37 children and adolescents with TS who were refractory to previous treatment that aripiprazole still reduced tics as well as explosive outbursts in these patients.…”
Section: Pharmacological Treatment Options For Tsmentioning
confidence: 99%
“…Aripiprazole has been reported to be less likely to cause weight gain in adults compared to other atypical neuroleptics (Kolotkin et al 2008). Recently, several case series and one openlabel study have reported on the use of aripiprazole in children and adolescents with TD or chronic tic disorder, but to date, no controlled trials have been reported (Hounie et al 2004;Dehning et al 2005;Kastrup et al 2005;Murphy et al 2005;Bubl et al 2006;Constant et al 2006;Davies et al 2006;Duane 2006;Fountoulakis et al 2006;Yoo et al 2006;Ben Djebara et al 2008;Budman et al 2008;Kawohl et al 2008;Seo et al 2008;Stenstrom and Sindo 2008;Winter et al 2008). These case reports and open-label series have suggested that aripiprazole at doses of 2.5-15 mg daily appears to reduce tic severity as judged by clinician rating scales.…”
Section: Introductionmentioning
confidence: 99%
“…It also has a high affinity with the serotonin receptor system, working as an antagonistic on 5-HT 2A receptors,95,96 and a partial agonistic on 5-HT 2C and 5-HT 1a receptors 97. Despite the lack of randomized double-blind and placebo-controlled studies, since 2004 more than 200 cases in at least 25 mostly open studies have been published, reporting good efficacy of aripiprazole in the treatment of tics for both adults and children 95,98120. For instance, one larger retrospective study describes tic reduction in 29 of the 37 patients, who all tolerated the drug and continued the treatment 95.…”
Section: Resultsmentioning
confidence: 99%